featured-image

Moderna, Inc. ( NASDAQ: MRNA ) Moderna Oncology Investor Event June 3, 2024 7:15 PM ET Company Participants Stephen Hoge - President Kyle Holen - Head of Development, Therapeutics and Oncology Michelle Brown - Vice President, INT Oncology Rose Loughlin - VP, R&D Strategy Lavina Talukdar - SVP & Head of IR Conference Call Participants Luca Issi - RBC Capital Markets Gena Wang - Barclays Dina Elmonshed - Jefferies Terence Flynn - Morgan Stanley Jess Fye - JPMorgan Myles Minter - William Blair Mani Foroohar - Leerink Partners Stephen Hoge We're going to get started. Thank you, everybody, for taking some time out of ASCO and your time here to spend with us.

I'm Stephen Hoge, I'm the President of Moderna. And I'm going to be providing a little bit of context upfront for the data we're going to be viewing today, which will cover our full oncology pipeline. We're incredibly excited to do that.



Before I dive in, we will be making forward-looking statements during this presentation. Those are covered by the Safe Harbor Act. You can find these slides and our reference to it on our website.

Okay. So over the last number of years, we have been building a pretty extensive pipeline. Now we're going to spend almost all of our time today in oncology, focused on INT because we have some exciting data, clinical data, and obviously the presentations from today.

And we're looking forward to questions on that. But we did want to take the opportunity today to give a sense of all of the other effor.

Back to Fashion Page